Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2019)
14 slides from Idt Australia's shareholder meeting presentation, Nov 18, 2019
Slide 1: IDT Australia Limited 2019 Annual General Meeting
@) IDT Australia Limited 2019 Annual General Meeting Ws I
Slide 2: Year in Review
Year in Review > % April 2018 Finalised divestment of ANDA portfolio August 2018 Medicinal cannabis manufacturing partnership secured with Cann Group Limited May 2018 IDT files Medicinal Cannabis Manufacturing Licence application with the Office of Drug Control September 2018 IDT launches Small Parc
Slide 3: Financial Results 2018 Executive Summary
Financial Results 2018 Executive Summary Revenue down 9% YoY Impacted by FY'18 ANDA divestment, increased US generic competition and FDA Warning Letter remediation activities One Time Expenses FDA Warning Letter now lifted Unprofitable ANDA portfolio and surplus equipment divested Operating Expenses
Slide 4: IDT Base Business 2018 Executive Summary
IDT Base Business 2018 Executive Summary ss 4 ‘a Commercial Active Pharmaceutical ingredient (API) Manufacturing = Commercial API manufacturing activities continue to provide IDT with profitable and steady baseload cw A”®@ Commercial Finished Dosage Form (FDF) Manufacturing ® FDF manufacturing acros
Slide 5: Medicinal Cannabis Plan
Medicinal Cannabis Plan Li— Executive Summary
Slide 6: IDT: A Centre of Excellence in Medicinal Cannabis Manufacturing
Goal iDT: A Centre of Excellence in Medicinal Cannabis Manufacturing OPPORTUNITY GMP* Manufactured (Medicinal) Cannabis products are mandatory for entry into highly regulated markets; and are emerging as a key market opportunity to convert lower value biomass into higher value differentiated product
Slide 7: IDT's Key Differentiators
Medicinal Cannabis Manufacturing IDT’s Key Differentiators » IDT’s Facilities, Capabilities and Licensure are already in place Critical equipment is installed, commissioned and validated IDT has a long history of GMP manufacturing and has been developing GMP medicinal cannabis products for over 2 ye
Slide 8: Medicinal Cannabis Business Model
Medicinal Cannabis Business Model ly MP CRUDE RESIN 1ST GEN PRODUCTS Local Market = Natural Oil (GMP) in Bottle = GMP Export = Winterised Oil (GMP) in Bottle @) = Bulk Oil (GMP) in Bottle _ o FINISHED ano cen propucts ym FILTERED OIL Winterised (de-waxed) Oil BULK -. Proprietary/Partnered DOSAGE ™ G
Slide 9: IDT Manufacturing Campus
IDT Manufacturing Campus tablished Medicinal Cannabis Infrastructure Medicinal cannabis TGA and FDA audited . . milling, packaging and approved quality .2ha freehold site, purpose built API and and finished dosage form system supporting the Potential site for nished dosage form manufacturing facilit
Slide 10: Requisite Facility Licensure In Place
Medicinal Cannabis Manufacturing Requisite Facility Licensure In Place IDT holds the following relevant facility licences: Therapeutic Goods Administration* Department of Health Office of Drug Control Medicinal Cannabis Manufacture Licence GMP Certification and Licences to Manufacture Therapeutic Go
Slide 11: The Year Ahead
The Year Ahead Drive and Grow The Business Focus on profitability and expanding IDT's Active Pharmaceutical Ingredient and Finished Dosage Form product offerings Scale-up activities to support medicinal cannabis resin extraction and downstream processing Continued Focus on Capital Management and Cos
Slide 12: Corporate Snapshot
IDT Australia Limited Corporate Snapshot June 2018 November 2019 Shares on issue Options Top twenty holders Share price (11 Nov 2019) Market cap Cash at hand (30 June 2019) 236,359,103 66% of IC
Slide 13: Board of Directors and Executive Team
IDT Australia Limited _SBoard of Directors < @x Alan Fisher Chair Finance specialist with key experience business restructuring and company urnarounds. —hr Hugh Burrill Pharma pipeline portfolio management Co product development. x Hospira/Mayne Pharma) s Mary Sontrop iopharmaceutical executive with
Slide 14: Disclaimer
DISCLAIMER This presentation contains forward looking statements which are subject to risks and uncertainties. Such statements involve known and unknown risks. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances and there ar